FIT Biotech’s strategy is to license its patented GTU® technology to partners to be used for medical applications, in particular for applications with high commercial potential targeted at existing large markets or markets with a need for more efficient, safer and less costly treatments.

The company primarily focuses on verifying the preclinical efficacy of its drug candidates (proof-of-concept) developed on the basis of the GTU® technology. After this, the company aims at licensing the drug candidate to pharmaceutical companies for further development and finally for sales. The company’s revenue model is based on the signing and milestone fees of the targeted license agreements as well as on royalties.

The drug candidate applications developed on the basis of the company’s GTU technology are applied in different gene-based treatments and vaccines.